#$%^&*AU2018250507A120181115.pdf#####C: Interwoven NRPortbl DCC DAR 17896604 l.docx-19 102018 ABSTRACT A method of treating a cancer in a subject is disclosed, comprising administering to the subject an immunomodulator and a second therapeutic agent, wherein: (i) the immunomodulator is chosen from one or more of: an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule, and (ii) the second therapeutic agent is LDK378, thereby treating the cancer.WO 2016/040880 PCT/US2015/049810 CD274 mRNA change in H3122 upon LDK378 Treatment 120.0 --------------------------------------------------------------------------------------------10 .0 -- --- --------------------- ------------------------------ -------------------a>； 80.0--- -- :-- --------------------- ------------------------------ ------------------40 0 -- - -- ------------------------ -- I-- ----- +----120.0--- ----- -------------------------- ---0.0 4.2 0.0 ----------------- -- --- ->； 0.0 Veh 20nM 1OOnM Veh 20nM 100nM Veh 20nM lOOnM 4hr 24hr 48hr EVeh 4hr M Veh 24hr ElVeh 48hr M20nM D20nM E20nM M100nM LlOOnM ElOOnM FIG. 1 1/1
